Marina Mojena
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marina Mojena.
Tetrahedron | 1992
Claude Dufresne; Kenneth E. Wilson; Deborah L. Zink; Jack L. Smith; James D. Bergstrom; Marc M. Kurtz; Deborah J. Rew; Mary Nallin; Rosalind G. Jenkins; Ken Bartizal; Charlotte Trainor; Gerald F. Bills; Maria S. Meinz; Leeyuan Huang; Janet C. Onishi; James A. Milligan; Marina Mojena; Fernando Pelaez
Abstract The novel zaragozic acid C ( 1 ) has been isolated as a potent inhibitor of squalene synthase. It was found to be a competitive inhibitor of rat liver squalene synthase with an apparent K i of 45 ± 15 pM, and a broad spectrum antifungal agent against both yeast and filamentous fungi.
Molecular Diversity | 2005
John G. Ondeyka; Kithsiri Herath; Hiranthi Jayasuriya; Jon D. Polishook; Gerald F. Bills; Anne W. Dombrowski; Marina Mojena; Gregory E. Koch; Jerry DiSalvo; Julie A. DeMartino; Ziqiang Guan; Weerachai Nanakorn; Cori M. Morenberg; Michael J. Balick; Dennis W. Stevenson; Marc Slattery; Robert P. Borris; Sheo B. Singh
The chemokines (CXCL9, CXCL10 and CXCL11) and associated CXCR3 receptor are expressed during the inflammatory process from multiple sclerosis, atherosclerosis or organ transplantation resulting in the recruitment of lymphocytes leading to tissue damage. It is hypothesized that blocking of the ligand/CXCR3 receptor interaction has potential to provide opportunity for development of agents that would block tissue rejection. In this paper, four classes of natural product inhibitors (IC50 ranging 0.1–41 μM) have been described that block the CXCR3 receptor interaction of IP-10 ligand. These include a cyclic thiopeptide (duramycin), polyketide glycosides (roselipins), steroidal glycosides (hypoglausin A and dioscin) and a novel alkyl pyridinium alkaloid that were isolated by bioassay-guided fractionation of the organic extracts derived from actinomycete, fungal, plant and marine sources and discovered using 125 I IP-10/CXCR3 binding assay. Duramycin was the most potent with an IC50 of 0.1 μM. Roselipins 2A, 2B and 1A showed IC50 values of 14.6, 23.5, and 41 μM, respectively. Diosgenin glycosides dioscin, hypoglaucin A and kallstroemin D exhibited IC50 values of 2.1, 0.47 and 3 μM, respectively. A novel cyclic 3-alkyl pyridinium salt isolated from a sponge displayed a binding IC50 of 0.67 μ M.
Fungal Biology | 1994
Gerald F. Bills; Fernando Pelaez; Jon D. Polishook; Maria Teresa Diez-Matas; Guy H. Harris; Wendy H. Clapp; Claude Dufresne; Kevin M. Byrne; Mary Nallin-Omstead; Rosalind G. Jenkins; Marina Mojena; Leeyuan Huang; James D. Bergstrom
The search for squalene synthase inhibitors of microbial origin has resulted in the discovery of a new class of fungal metabolites, the zaragozic acids (squalestatins). During our survey of representatives of most major groups of fungi and filamentous bacteria, the zaragozic acids were not found in prokaryotes Zygomycotina, or Basidiomycotina. All the fungal producers encountered to date are Ascomycotina, their related anamorphic states or sterile organisms with ascomycete affinities. Members of at least II different taxa of fungi are capable of making zaragozic acids. Zaragozic acid A (squalestatin 1) appears to be the most prevalent among the different fungal taxa. In several cases we have observed production in multiple strains of the same species; for example, nearly all strains of Sporormiella intermedia, that we have examined, produce zaragozic acid B. The discovery of the zaragozic acids illustrates how knowledge of fungal biology and biochemistry can enhance the search for new chemical entities. Simultaneous screening of fungi from diverse phylogenetic and ecological origins was emphasized to discover new zaragozic acids rather than simply relying on organisms from a single kind of substratum from geographically disparate sources.
Endocrinology | 2005
Fang Chen; Kristin Knecht; Elizabeth T. Birzin; John E. Fisher; Hilary A. Wilkinson; Marina Mojena; Consuelo Tudela Moreno; Azriel Schmidt; Shun-ichi Harada; Leonard P. Freedman; Alfred A. Reszka
Journal of Natural Products | 1993
Claude Dufresne; Kenneth E. Wilson; Sheo B. Singh; Deborah L. Zink; James D. Bergstrom; Deborah J. Rew; Jon D. Polishook; Maria S. Meinz; Leeyuan Huang; Keith C. Silverman; Russell B. Lingham; Marina Mojena; Carmen Cascales; Fernando Pelaez; Jackson B. Gibbs
Journal of Biological Chemistry | 2001
Antonio Castrillo; Marina Mojena; Sonsoles Hortelano; Lisardo Boscá
Bioorganic & Medicinal Chemistry Letters | 2006
Robert R. Wilkening; Ronald W. Ratcliffe; A.K. Fried; Dongfang Meng; Wanying Sun; Lawrence F. Colwell; Sherrie Lambert; Mark L. Greenlee; Stefan Nilsson; Ann-Gerd Thorsell; Marina Mojena; Consuelo Tudela; Katalin Frisch; Wanda W.-S. Chan; Elizabeth T. Birzin; Susan P. Rohrer; Milton L. Hammond
Bioorganic & Medicinal Chemistry Letters | 2006
Timothy A. Blizzard; Candido Gude; Jerry D. Morgan; Wanda Chan; Elizabeth T. Birzin; Marina Mojena; Consuelo Tudela; Fang Chen; Kristin Knecht; Qin Su; Bryan Kraker; Ralph T. Mosley; Mark A. Holmes; Nandini Sharma; Paula M. D. Fitzgerald; Susan P. Rohrer; Milton L. Hammond
Archive | 1998
Gerald Bills; Maria Teresa Diez; Anne W. Dombrowski; Nicole D Falconi; Michael A. Goetz; David C. Heimbrook; Otto D. Hensens; Leeyuan Huang; Hans E. Huber; Rosalind G. Jenkins; Richard L. Kendall; Seok H. Lee; Marina Mojena; Allen Oliff; Denis R. Patrick; Fernando Pelaez; Jr Kenneth A Thomas; Dolores Vilella; Annie Z. Zhao; Deborah L. Zink
Botany | 1995
Leeyuan Huang; Russell B. Lingham; Guy H. Harris; Sheo B. Singh; Claude Dufresne; Mary Nallin-Omstead; Gerald F. Bills; Marina Mojena; Manuel Sanchez; John D. Karkas; Jackson B. Gibbs; Wendy H. Clapp; Maria S. Meinz; Keith C. Silverman; James D. Bergstrom